Transitioning from Glipizide to Tirzepatide and Empagliflozin in Type 2 Diabetes
Discontinue glipizide completely when initiating tirzepatide (Mounjaro) and empagliflozin (Jardiance) to prevent hypoglycemia, as sulfonylureas significantly increase hypoglycemia risk when combined with these agents. 1
Discontinuing Glipizide
Stop glipizide entirely at the time of initiating tirzepatide or empagliflozin. The KDIGO 2020 guidelines explicitly state that for patients meeting glycemic targets who are treated with sulfonylureas, it is necessary to stop or reduce the dose of antihyperglycemic drugs other than metformin to facilitate addition of an SGLT2 inhibitor 1. The same principle applies when adding GLP-1 receptor agonists, as the risk of hypoglycemia increases markedly when these agents are combined with sulfonylureas 1.
- Do not attempt dose reduction of glipizide—complete discontinuation is the safest approach 1
- The glucose-lowering effect of tirzepatide alone (HbA1c reduction of 1.9–2.2%) is sufficient to replace sulfonylurea therapy 2
Initiating Empagliflozin (Jardiance)
Start empagliflozin at 10 mg once daily in the morning, taken with or without food. 3
- The dose may be increased to 25 mg once daily if additional glycemic control is needed after tolerating the 10 mg dose 3
- Assess renal function before initiation: empagliflozin should not be initiated if eGFR is below 20 mL/min/1.73 m² 3
- For glycemic control specifically, empagliflozin is not recommended if eGFR is below 30 mL/min/1.73 m², though it may be continued for cardiovascular and renal benefits 3
- Check volume status: correct any volume depletion before starting empagliflozin to reduce risk of hypotension and acute kidney injury 1
Monitoring Empagliflozin
- A reversible decrease in eGFR of 1–3 mL/min/1.73 m² may occur in the first 12–16 weeks and is not an indication to discontinue therapy 1, 4
- Monitor renal function at least every 3–6 months in patients with eGFR below 60 mL/min/1.73 m² 1
- Educate patients about symptoms of volume depletion, genital mycotic infections, and urinary tract infections 3
- Withhold empagliflozin during prolonged fasting, surgery, or critical illness due to increased ketoacidosis risk 1
Initiating Tirzepatide (Mounjaro)
Start tirzepatide at 2.5 mg subcutaneously once weekly, then escalate by 2.5 mg every 4 weeks until reaching the target maintenance dose of 10 mg or 15 mg weekly. 2, 5
Dose Escalation Schedule
- Weeks 0–3: 2.5 mg once weekly 2, 5
- Weeks 4–7: 5 mg once weekly 2, 5
- Weeks 8–11: 7.5 mg once weekly 2, 5
- Week 12 onward: 10 mg once weekly (or continue to 15 mg if additional glycemic control is needed) 2, 5
The slower dose escalation (advancing no faster than every 4 weeks) minimizes gastrointestinal side effects, which occur in 20–30% of patients and are the most common reason for discontinuation 2, 4. Nausea, vomiting, and diarrhea are most pronounced during dose escalation and typically improve with continued treatment 2, 4.
Renal Considerations for Tirzepatide
- No dose adjustment is required for any level of renal impairment, including eGFR below 15 mL/min/1.73 m² and dialysis, because tirzepatide is cleared primarily by proteolysis 4
- Tirzepatide is preferred over empagliflozin in advanced CKD (eGFR below 30 mL/min/1.73 m²) because it maintains glycemic efficacy and provides cardiovascular protection without relying on renal filtration 6, 4
Monitoring Tirzepatide
- Monitor for gastrointestinal symptoms, particularly during the first 8 weeks of treatment 2, 4
- Do not advance the dose faster than every 4 weeks, as rapid escalation increases the risk of severe nausea, vomiting, and potential volume depletion-related acute kidney injury 4, 5
- Hypoglycemia risk is low with tirzepatide monotherapy but increases when combined with insulin or sulfonylureas—hence the need to discontinue glipizide 1, 4
Sequencing the Initiation
Initiate both agents simultaneously on the same day after discontinuing glipizide. 1
- There is no need to stagger the start dates of empagliflozin and tirzepatide 1
- Both agents have complementary mechanisms: empagliflozin provides cardiovascular and renal protection with modest glycemic benefit, while tirzepatide delivers robust glycemic control and weight reduction 7, 6
- The combination is supported by KDIGO 2020 and ADA 2025 guidelines, which recommend SGLT2 inhibitors and GLP-1 receptor agonists as foundational therapy in patients with type 2 diabetes and cardiovascular or renal disease 1, 6
Common Pitfalls to Avoid
- Do not continue glipizide at any dose when starting tirzepatide or empagliflozin, as this dramatically increases hypoglycemia risk 1
- Do not reduce the tirzepatide dose in patients with renal impairment—no adjustment is needed 4
- Do not discontinue empagliflozin if eGFR declines by 1–3 mL/min/1.73 m² in the first few months, as this is an expected hemodynamic effect 1, 4
- Do not escalate tirzepatide faster than every 4 weeks, as this increases gastrointestinal intolerance and discontinuation rates 2, 4, 5
- Do not co-prescribe DPP-4 inhibitors (e.g., sitagliptin) with tirzepatide, as they share the incretin pathway and provide no additive benefit 1
Rationale for This Approach
The KDIGO 2020 guidelines prioritize SGLT2 inhibitors and GLP-1 receptor agonists over sulfonylureas in patients with type 2 diabetes and chronic kidney disease due to superior cardiovascular and renal outcomes 1, 7. Sulfonylureas like glipizide carry a 17–23% incidence of hypoglycemia compared to 4.6–6.2% with newer agents 8. Tirzepatide has demonstrated HbA1c reductions of 1.9–2.2% with weight loss of 12.8–14.7% in patients with type 2 diabetes, far exceeding the efficacy of sulfonylureas 2. Empagliflozin reduces cardiovascular death by 38% and heart failure hospitalization by 35% in patients with established cardiovascular disease 9. The combination of these agents addresses glycemic control, cardiovascular protection, renal preservation, and weight management—outcomes that glipizide cannot provide 1, 7, 6.